Loomis, Sayles & Company
MRNA icon

Loomis, Sayles & Company’s Moderna MRNA Stock Holding History

Loomis, Sayles & Company’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-45
Closed -$5K – 983
2023
Q2 		$5K Sell
45
-92
-67% -$12.3K ﹤0.01% 852
2023
Q1 		$21K Buy
137
+87
+174% +$14.4K ﹤0.01% 730
2022
Q4 		$9K Sell
50
-861
-95% -$141K ﹤0.01% 796
2022
Q3 		$108K Buy
911
+885
+3,404% +$134K ﹤0.01% 515
2022
Q2 		$4K Hold
26
– – ﹤0.01% 748
2022
Q1 		$4K Sell
26
-725
-97% -$122K ﹤0.01% 819
2021
Q4 		$191K Buy
751
+239
+47% +$69.9K ﹤0.01% 556
2021
Q3 		$197K Sell
512
-306
-37% -$113K ﹤0.01% 523
2021
Q2 		$192K Sell
818
-68
-8% -$12.2K ﹤0.01% 523
2021
Q1 		$116K Buy
886
+702
+382% +$102K ﹤0.01% 549
2020
Q4 		$19K Buy
+184
New +$18.6K ﹤0.01% 628

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Loomis, Sayles & Company's MRNA Position: Q3 2023 in Review

Loomis, Sayles & Company sold out of Moderna (MRNA) in Q3 2023, closing a stake of 45 shares — an estimated $5K sold.

Loomis, Sayles & Company first reported a position in MRNA in Q4 2020 and held it in 11 quarters. The position peaked at $197K in Q3 2021. 889 funds tracked by Wall St. Rank hold MRNA as of Q3 2023.

  • Loomis, Sayles & Company reported no remaining Moderna position as of Q3 2023 after selling out during the quarter.
  • Loomis, Sayles & Company sold 45 Moderna shares in Q3 2023, an estimated $5K.
  • Loomis, Sayles & Company first reported a position in Moderna in Q4 2020 and held it in 11 quarters.
  • Loomis, Sayles & Company's Moderna position peaked at $197K in Q3 2021.
  • 889 funds tracked by Wall St. Rank held Moderna as of Q3 2023.

Based on Loomis, Sayles & Company's 13F filing for Q3 2023, filed 9 Nov 2023.